communityacquir
pneumonia
still
signific
caus
morbid
mortal
often
misdiagnos
inappropri
treat
although
caus
wide
varieti
microorgan
pneumococcu
atyp
mycoplasma
pneumonia
chlamydophila
pneumonia
staphylococcu
aureu
certain
gramneg
rod
usual
pathogen
encount
siteofcar
decis
critic
determin
site
type
care
well
extent
diagnost
workup
antimicrobi
therapi
start
soon
possibl
particularli
requir
admiss
hospit
typic
physician
know
degre
certainti
ident
etiolog
pathogen
number
nation
guidelin
publish
help
physician
choic
initi
drug
modifi
necessari
pathogen
antimicrobi
suscept
pattern
becom
known
adjunct
therapi
pressor
fluid
replac
valu
macrolid
appear
help
well
like
secondari
immunomodulatori
effect
recent
data
also
suggest
role
steroid
pneumonia
definit
infect
lung
pulmonari
parenchyma
recent
consid
either
communityacquir
pneumonia
cap
hospit
andor
ventil
acquir
pneumonia
hapvap
note
subgroup
outpati
contact
healthcar
system
present
pneumonia
caus
organ
similar
caus
hap
cap
new
categori
pneumonia
call
healthcareassoci
pneumonia
hcap
defin
howev
recent
data
rais
question
whether
concern
regard
type
pathogen
resist
pattern
hcap
fact
hold
like
subgroup
modifi
consider
cap
common
infect
often
misdiagnos
inappropri
treat
often
present
rel
mild
ill
overal
still
remain
caus
consider
morbid
mortal
report
diseas
data
exact
estim
year
million
case
occur
usa
million
hospit
death
pneumonia
influenza
typic
case
treat
outpati
hospit
set
overal
mortal
rate
outpati
cap
region
ill
enough
requir
hospit
mortal
rate
report
incid
rate
greatest
extrem
age
overal
rate
adult
usa
case
per
person
per
year
high
per
among
children
year
per
among
year
although
larg
number
microbi
pathogen
associ
cap
immunocompet
patient
list
rel
short
reason
stabl
newer
pathogen
document
includ
hantaviru
human
metapneumoviru
coronaviru
associ
sar
recent
middl
east
respiratori
syndrom
communityacquir
strain
methicillinresist
staphylococcu
aureu
mrsa
also
becom
cap
pathogen
rel
recent
case
cap
howev
caus
pathogen
mention
tabl
advent
polymeras
chain
reaction
pcr
detect
virus
respiratori
sampl
increas
significantli
studi
virus
found
onethird
adult
cap
patient
presenc
viru
howev
prove
causal
nasopharyng
swab
yield
respiratori
virus
healthi
adult
interestingli
mix
infect
bacteri
viral
organ
found
cap
case
tend
associ
sever
infect
caus
bacterium
potenti
viral
pathogen
influenza
import
although
respiratori
syncyti
viru
adeno
parainfluenza
corona
virus
may
also
role
play
although
influenza
viru
certainli
capabl
caus
pneumonia
sever
one
often
seen
primari
infect
becom
secondarili
infect
bacterium
aureu
streptococcu
pneumonia
tabl
taken
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
cap
guidelin
although
respiratori
virus
influenza
includ
footnot
tabl
believ
proper
consid
influenza
viru
particular
potenti
caus
sever
intens
care
unit
icu
pneumonia
well
simplifi
matter
somewhat
separ
etiolog
agent
typic
bacteri
pathogen
atyp
pathogen
former
group
includ
pneumonia
common
identifi
bacteria
bacteria
haemophilu
influenza
aureu
gramneg
rod
klebsiella
pneumonia
pseudomona
aeruginosa
anaerob
anaerob
bacteria
may
seen
case
gross
aspir
pneumonia
patient
unprotect
airway
seizur
substanc
alcohol
abus
andor
gingiv
worth
note
pneumonia
seem
decreas
frequenc
widespread
use
pneumococc
vaccin
atyp
pathogen
pneumonia
chlamydophila
pneumonia
becom
import
particularli
young
adult
atyp
legionella
varieti
viral
pathogen
play
role
well
gener
fungal
protozo
infect
usual
seen
normal
host
cap
except
specif
circumst
coccidioidomycosi
cryptococcosi
pcr
studi
show
viral
pathogen
may
present
cap
patient
whether
etiolog
agent
copathogen
simpli
colon
alway
determin
discuss
individu
pathogen
beyond
scope
articl
certain
risk
factor
epidemiolog
circumst
identifi
cap
patient
risk
factor
cap
includ
alcohol
asthma
immunosuppress
institution
age
year
crowd
live
condit
close
contact
children
import
realiz
pneumonia
certainli
old
man
friend
shown
elderli
cap
patient
requir
hospit
overal
mortal
rate
greater
gener
hospit
popul
enhanc
mortal
extend
year
thought
may
least
partial
explain
increas
vascular
event
includ
myocardi
infarct
stroke
possibl
result
overal
enhanc
system
inflammatori
respons
patient
risk
factor
pneumococc
pneumonia
includ
dementia
seizur
cerebrovascular
diseas
heart
failur
alcohol
smoke
chronic
obstruct
pulmonari
diseas
hiv
infect
communityassoci
mrsa
like
seen
patient
colon
organ
gramneg
bacilli
like
p
aeruginosa
typic
seen
patient
sever
structur
lung
diseas
bronchiectasi
cystic
fibrosi
pneumonia
occur
pathogen
must
reach
alveoli
multipli
incit
host
respons
access
lower
airway
occur
number
way
includ
inhal
aspir
direct
inocul
hematogen
contigu
spread
adjac
focu
direct
inocul
might
occur
penetr
thorac
injuri
spread
contigu
focu
infect
mediastin
may
occur
unusu
hematogen
spread
case
tricuspid
endocard
might
seen
iv
drug
abus
like
rout
howev
small
volum
aspir
bacteria
patient
oropharynx
occur
sleep
inhal
contamin
droplet
protect
occurr
depend
larg
extent
mechan
mechan
supplement
innat
acquir
host
defens
nasal
hair
turbin
intact
gag
cough
reflex
branch
tracheobronchi
tree
effici
mucociliari
clearanc
mechan
play
larg
role
keep
pathogen
bay
gut
normal
oropharyng
colon
microbi
flora
play
role
hold
potenti
pathogen
pathogen
gain
access
alveoli
resid
alveolar
macrophag
surfact
protein
sp
enter
fray
surfact
gener
act
lower
surfac
tension
two
liquid
liquidsolid
interfac
sp
collagen
glycoprotein
play
number
role
lung
felt
take
part
innat
immun
clear
apoptot
cell
bind
nonself
structur
bacteria
fungi
defens
also
unsuccess
infect
challeng
persist
inflammatori
respons
patient
come
play
account
ultim
sign
symptom
pneumonia
proinflammatori
cytokin
respons
excess
process
may
progress
sepsi
organ
failur
possibl
shock
even
death
case
sever
infect
variou
inflammatori
mediat
includ
tnf
granulocytecoloni
stimul
factor
result
fever
releas
neutrophil
attract
lung
alveolarcapillari
leak
may
develop
result
fill
alveoli
subsequ
hypoxemia
find
pneumonia
auscult
chest
xray
process
sever
secondari
chang
lung
volum
complianc
may
eventu
result
patient
demis
pneumon
process
number
phase
occur
tissu
level
initi
edema
caus
presenc
proteinac
exud
alveoli
follow
phase
red
hepat
caus
presenc
mani
red
cell
follow
gray
hepat
phase
red
cell
lyse
degrad
neutrophil
fibrin
deposit
begin
domin
next
resolut
phase
macrophag
take
debri
clear
inflammatori
respons
subsid
inflammatori
respons
infect
primarili
respons
variou
clinic
find
cap
depend
host
extent
pathogen
diseas
vari
present
reason
benign
fulmin
mild
fatal
sever
variou
sign
symptom
encount
involv
lung
may
constitut
well
typic
patient
elev
temperatur
heart
rate
may
note
chill
well
myalgia
arthralgia
may
cough
short
breath
former
may
vari
nonproduct
product
purul
possibl
bloodting
sputum
chest
pain
may
occur
secondari
cough
pleurit
involv
interestingli
cap
patient
may
experi
gastrointestin
symptom
form
nausea
vomit
diarrhea
examin
find
depend
extent
local
involv
pulmonari
parenchyma
presenc
absenc
effus
well
extent
system
respons
releas
cytokin
inspect
patient
may
flush
andor
cyanot
may
use
accessori
muscl
respir
palpat
tactil
fremitu
may
note
dull
flat
percuss
note
may
indic
consolid
pleural
effus
respect
listen
chest
one
may
hear
rale
rhonchi
bronchial
breath
sound
possibl
pleural
friction
rub
physic
examin
mislead
neither
particularli
sensit
specif
pneumonia
elderli
especi
clinic
present
find
examin
may
mislead
elderli
patient
may
simpli
present
confus
medic
ill
diagnosi
usual
base
inform
obtain
care
histori
physic
examin
appropri
laboratori
test
procedur
case
cap
similar
approach
use
modifi
necessari
base
sever
initi
present
patient
possibl
cap
patient
physician
must
basic
ask
two
question
pneumonia
likeliest
pathogen
former
question
typic
answer
use
clinic
radiograph
method
latter
requir
use
laboratori
test
andor
certain
procedur
physician
must
tri
determin
patient
infect
noninfecti
ill
account
sign
symptom
entiti
may
mistaken
cap
includ
acut
bronchiti
acut
exacerb
chronic
bronchiti
radiat
pneumon
congest
heart
failur
pulmonari
emboli
name
usual
diagnosi
cap
base
upon
find
suggest
infect
fever
chill
increas
white
count
plu
sign
andor
symptom
local
respiratori
system
includ
cough
short
breath
increas
sputum
product
abnorm
physic
examin
new
chang
infiltr
chest
radiograph
occasion
radiograph
find
may
suggest
particular
pathogen
exampl
upper
lobe
caviti
tuberculosi
pneumotocel
aureu
sensit
specif
physic
examin
howev
good
valu
respect
use
clinic
syndrom
approach
allow
one
determin
pathogen
reliabl
usual
determin
patient
cap
antibiot
treatment
must
start
empir
basi
sinc
physician
know
degre
certainti
pathogen
patient
manag
commun
costeffect
test
investig
histori
physic
examin
chest
xray
patient
admit
hospit
particularli
icu
addit
test
done
identifi
unexpect
pathogen
allow
specif
antimicrobi
treatment
given
decreas
antibiot
select
pressur
result
treatment
organ
might
otherwis
miss
public
health
issu
address
document
organ
mycobacterium
tuberculosi
influenza
anoth
import
reason
tri
identifi
pathogen
without
suscept
data
trend
antimicrobi
resist
document
follow
accur
follow
avail
testsprocedur
help
identifi
cap
pathogen
depend
upon
circumst
sever
ill
appropri
test
sampl
obtain
quickli
possibl
treatment
start
test
expector
sputum
limit
sinc
seri
patient
may
unabl
produc
appropri
sampl
polymorphonuclear
leukocyt
squamou
epitheli
cell
per
low
power
field
case
patient
might
alreadi
start
antibiot
use
famili
member
drug
data
base
hospit
cap
patient
reveal
case
pathogen
found
case
admit
icu
intub
deep
suction
aspir
bal
sampl
rel
highyield
procedur
depend
upon
circumst
stain
exampl
tuberculosi
fungi
may
done
well
yield
blood
cultur
surprisingli
poor
overal
blood
cultur
hospit
patient
posit
although
yield
tend
higher
case
aureu
pneumonia
rel
low
yield
overal
low
impact
treatment
outcom
blood
cultur
recommend
hospit
cap
patient
certain
higher
risk
patient
asplenia
chronic
liver
diseas
complement
defici
decreas
white
count
secondari
pneumonia
sever
cap
blood
cultur
done
antigen
pneumococcu
legionella
pneumophila
serogroup
detect
urin
sensit
specif
valu
respect
advantag
test
abl
detect
antigen
even
antibiot
treatment
start
test
amplifi
nucleic
acid
pathogen
allow
rapid
accur
identif
commerci
avail
pcr
kit
identifi
certain
respiratori
virus
includ
influenza
well
pneumonia
c
pneumonia
despit
rapid
sensit
specif
one
major
problem
pcr
distinguish
colon
actual
pathogen
clinic
judgment
would
exercis
whenev
pcr
use
serolog
test
gener
depend
upon
rise
usual
fourfold
igm
antibodi
acut
convalesc
phase
serum
sampl
gener
less
frequent
use
especi
pneumonia
accuraci
issu
time
requir
convalesc
sampl
obtain
number
biomark
identifi
although
two
frequent
use
case
pneumonia
procalcitonin
pct
creactiv
protein
like
biomark
consid
indic
inflamm
consid
help
certain
circumst
diagnosi
infect
initi
stop
antimicrobi
therapi
pct
produc
part
host
respons
bacteri
viral
infect
individu
trial
cochran
metaanalysi
shown
use
pct
manag
cap
result
less
antibiot
use
without
increas
mortal
review
random
control
trial
n
patient
assess
use
pct
algorithm
antibiot
decis
show
appropri
use
biomark
reduc
amount
antibiot
use
without
increas
mortal
recommend
base
pct
made
accord
whether
patient
moder
highacu
pulmonari
infect
high
risk
sepsi
icu
cutoff
moderateacu
group
ugl
highacu
group
recommend
antibiot
use
cutoff
strongli
discourag
discourag
encourag
strongli
encourag
moderateacu
group
test
recommend
everi
day
antibiot
stop
level
drop
least
peak
valu
patient
show
clinic
improv
highacu
group
specif
frequenc
test
given
recommend
period
monitor
antibiot
could
discontinu
level
drop
baselin
patient
exhibit
posit
clinic
respons
fewer
data
avail
regard
util
creactiv
protein
pneumonia
present
seem
sensit
pct
diagnosi
bacteri
pneumonia
test
must
interpret
conjunct
clinic
present
inform
avail
regard
patient
cap
hard
fast
rule
use
variou
test
although
gener
virtual
none
would
use
outpati
cap
admit
hospit
center
particular
tri
get
appropri
respiratori
secret
sampl
stain
cultur
expector
deep
suction
bronchoscopi
patient
intub
howev
delay
treatment
sampl
unobtain
whatev
reason
tend
blood
cultur
patient
admit
hospit
certainli
patient
admit
icu
gener
rule
urin
antigen
test
routin
hospit
patient
center
quit
routin
use
serolog
test
routin
reli
biomark
although
center
particularli
europ
biomark
follow
close
use
pcr
test
vari
quit
bit
center
center
becom
standard
point
canadian
center
diagnosi
cap
made
extent
type
investig
well
type
treatment
depend
upon
site
care
outpati
hospit
set
ward
icu
rather
use
subject
assess
done
past
physician
number
predict
tool
avail
help
decis
two
best
known
pneumonia
sever
index
psi
psi
initi
develop
identifi
cap
patient
well
enough
treat
commun
true
sever
ill
score
assign
point
patient
base
variou
criteria
similar
end
psi
use
variabl
releg
patient
categori
use
variabl
put
patient
categori
pro
con
although
easier
use
perform
quit
well
patient
neither
particularli
good
determin
need
icu
care
whichev
tool
one
choos
factor
must
also
consid
relev
particular
patient
abil
compli
oral
antibiot
regimen
resourc
avail
patient
commun
set
problem
psi
provid
snapshot
happen
patient
time
assess
carri
combin
measur
biomark
may
improv
discriminatori
power
proadrenomedullin
member
calcitonin
famili
act
either
hormon
cytokin
depend
upon
circumst
surround
product
swiss
studi
combin
score
level
proadrenomedulli
show
better
risk
predict
relat
advers
event
mortal
cap
admiss
icu
major
minor
criteria
propos
idsaat
guidelin
includ
one
two
major
criteria
septic
shock
need
mechan
ventil
presenc
three
nine
minor
criteria
whenev
assess
cap
patient
regard
site
care
kept
mind
situat
may
chang
patient
condit
may
suddenli
deterior
patient
admit
initi
floor
set
subsequ
worsen
lower
surviv
rate
equal
ill
patient
care
icu
set
resist
antimicrobi
resist
certainli
new
issu
anyth
continu
threaten
util
drug
avail
us
need
minim
resist
one
best
argument
effect
antibiot
stewardship
program
resist
problem
consid
point
view
pathogen
drug
cap
organ
interest
primarili
pneumonia
atyp
pneumonia
also
aureu
certain
gramneg
rod
usual
drug
class
use
cap
includ
blactam
macrolid
fluoroquinolon
tetracyclin
organ
resist
drug
three
antimicrobi
class
differ
mechan
action
consid
multidrug
resist
pneumococcu
chang
break
point
penicillin
nonmening
isol
mgml
suscept
intermedi
resist
respect
dramat
etc
increas
proport
pneumococc
isol
consid
sensit
pneumococc
resist
blactam
result
low
affin
penicillinbind
protein
resist
macrolid
mediat
chang
target
site
presenc
efflux
mechan
target
site
modif
encod
ermb
gene
result
ribosom
methyl
rrna
high
level
mic
mgml
resist
mef
gene
respons
efflux
antibiot
lowlevel
resist
mic
mgml
pneumococc
macrolid
resist
increas
worldwid
although
north
america
tend
often
phenotyp
lowlevel
resist
varieti
elsewher
commonli
highlevel
varieti
mycoplasma
resist
macrolid
well
document
well
due
mutat
bind
posit
domain
v
rrna
aureu
develop
resist
virtual
blactam
except
ceftarolin
meca
gene
refer
mrsa
methicillin
one
origin
penicillinaseresist
semisynthet
penicillin
hospitaland
communityacquir
mrsa
strain
communityacquir
strain
gener
less
resist
hospitalacquir
one
often
suscept
clindamycin
trimethoprimsulfamethoxazol
tetracyclin
cephalosporin
ceftarolin
well
linezolid
vancomycin
also
usual
sensit
daptomycin
drug
inactiv
surfact
use
treatment
pneumonia
gramneg
bacilli
includ
p
aeruginosa
caus
cap
may
treat
varieti
drug
includ
thirdgener
cephalosporin
antipseudomon
penicillin
carbapenem
fluoroquinolon
fluoroquinolon
work
bind
dna
gyras
topoisomeras
iv
ultim
interf
bacteri
replic
mutat
either
lead
resist
alreadi
mention
physician
usual
know
certainti
etiolog
pathogen
treatment
initi
effect
educ
guess
situat
nation
guidelin
prepar
number
countri
help
physician
decis
canada
usa
initi
coverag
alway
includ
pneumococcu
atyp
mycoplasma
chlamydophila
legionella
guidelin
certain
european
countri
exampl
sweden
uk
call
coverag
routin
differ
gener
base
local
epidemiolog
data
north
american
approach
support
retrospect
data
administr
databas
includ
thousand
patient
sever
individu
studi
support
well
recent
paper
cap
new
england
journal
medicin
refer
idsaat
cap
guidelin
author
state
littl
chang
regard
antibiot
treatment
cap
recommend
articl
gener
consist
guidelin
last
month
howev
increas
interest
treatment
cap
patient
requir
hospit
icu
care
particular
question
blactammacrolid
combin
therapi
versu
blactam
monotherapi
rais
sever
studi
support
combin
treatment
especi
macrolid
part
regimen
metaanalysi
studi
involv
almost
patient
report
blactammacrolid
combin
reduc
mortal
significantli
benefit
seen
nonicu
icu
patient
garin
et
al
recent
report
result
random
control
trial
jama
compar
blactammacrolid
versu
blactam
alon
treatment
moder
sever
cap
studi
fail
find
noninferior
monotherapi
regimen
primari
outcom
measur
proport
patient
reach
clinic
stabil
day
recent
studi
new
england
journal
medicin
address
question
use
differ
experiment
design
differ
primari
outcom
design
clusterrandom
crossov
trial
strategi
rotat
period
primari
outcom
mortal
studi
blactam
monotherapi
noninferior
either
blactammacrolid
combin
fluoroquinolon
alon
studi
howev
atyp
found
patient
overal
sever
particularli
high
mean
psi
score
respect
treatment
start
soon
possibl
patient
admit
hospit
initi
dose
given
emerg
room
avoid
delay
refer
tabl
treatment
cap
recommend
given
tabl
idsaat
guidelin
pathogen
identifi
suscept
data
becom
avail
consider
given
deescal
streamlin
antimicrobi
therapi
target
regimen
case
howev
must
temper
concern
possibl
copathogen
obvious
also
depend
clinic
respons
patient
mrsa
possibl
either
vancomycin
linezolid
may
use
although
suggest
linezolid
may
effect
certainli
easier
use
given
either
iv
po
dose
need
adjust
base
renal
function
anoth
option
could
vancomycin
plu
clindamycin
latter
drug
ad
suppress
staphylococcu
toxin
format
p
aeruginosa
possibl
hope
maxim
antibiot
suscept
possibl
provid
addit
synergist
effect
well
dual
coverag
recommend
initi
pseudomona
document
patient
respond
treatment
regimen
narrow
appropri
monotherapi
base
upon
suscept
result
patient
clinic
cours
length
treatment
otherwis
uncompl
case
typic
day
case
document
bacteremia
particularli
pathogen
aureu
p
aeruginosa
treatment
given
week
respect
influenza
suspect
either
pathogen
copathogen
antivir
treatment
given
patient
meet
follow
criteria
requir
hospit
sever
complic
ill
age
year
pregnant
women
week
postpartum
patient
longterm
care
facil
varieti
medic
condit
reader
refer
recommend
advisori
committe
immun
practic
detail
discuss
issu
treatment
neuraminidas
inhibitor
zanamivir
oseltamivir
start
soon
possibl
given
day
despit
antimicrobi
drug
gener
quit
effect
erad
micorgan
cap
continu
signific
caus
morbid
mortal
discuss
section
pathophysiolog
much
due
host
respons
either
overreact
result
cytokin
storm
enter
period
quiescenc
immunoparalysi
lead
problem
adjunct
therapi
measur
develop
help
sustain
patient
exampl
vasopressor
fluid
replac
attempt
modul
host
inflammatori
respons
good
exampl
success
role
play
macrolid
number
immunomodulatori
effect
includ
alter
cytokin
express
leukocyt
function
apoptosi
benefit
drug
first
document
treatment
panbronchiol
increas
risk
cardiac
event
associ
cap
attribut
heighten
inflammatori
state
sinc
statin
antiinflammatori
activ
hope
use
might
mitig
effect
poor
outcom
data
conflict
somewhat
confus
gener
statin
felt
play
import
role
least
proactiv
treatment
point
view
one
paper
provid
metaanalysi
role
statin
prevent
treatment
cap
reveal
benefici
role
risk
develop
mortal
cap
author
admiss
result
constitut
low
qualit
evid
per
grade
framework
recent
two
multicent
doubleblind
random
placebocontrol
trial
shown
benefit
steroid
manag
cap
lancet
studi
random
hospit
cap
patient
prednison
mg
daili
placebo
week
jama
studi
sever
cap
employ
iv
methylprednisolon
h
day
versu
placebo
primari
outcom
measur
time
clinic
stabil
treatment
failur
respect
steroid
show
statist
signific
benefit
set
two
studi
unfortun
stori
posit
agent
tri
includ
nonsteroid
antiinflammatori
drotrecogin
alfa
activ
tifacogin
recombin
tissu
factor
pathway
inhibitor
number
factor
determin
prognosi
cap
includ
patient
age
gener
state
health
whether
treatment
given
outpati
inpati
set
extrem
vari
young
healthi
patient
well
enough
treat
home
elderli
patient
comorbid
condit
requir
admiss
icu
overal
mortal
rate
outpati
inpati
rang
overal
rate
approxim
fortun
two
vaccin
influenza
pneumococcu
avail
help
problem
cap
influenza
vaccin
typic
given
yearli
inactiv
viru
quit
effect
prevent
attenu
influenza
pneumococc
vaccin
avail
pneumococc
polysaccharid
vaccin
protein
conjug
vaccin
pcv
polysaccharid
vaccin
contain
capsular
materi
pneumococc
serotyp
conjug
vaccin
capsular
polysaccharid
frequent
strain
encount
children
link
immunogen
protein
result
product
tcelldepend
antigen
longterm
immunolog
memori
extens
use
particular
vaccin
infant
children
result
herd
immun
reduct
rate
pneumococc
pneumonia
sinc
pcv
stimul
mucos
immun
therebi
prevent
colon
carriag
vaccin
pneumococc
serotyp
open
creat
nonvaccin
pneumococc
serotyp
colon
patient
potenti
caus
diseas
use
result
signific
reduct
burden
pneumococc
diseas
concern
benefit
might
cost
increas
diseas
caus
nonvaccin
serotyp
overal
pneumococc
conjug
vaccin
posit
effect
mediat
part
herd
immun
result
greater
declin
pneumococc
diseas
due
vaccin
serotyp
older
children
adult
recommend
advisori
committe
immun
practic
follow
influenza
pneumococc
vaccin
although
understand
etiolog
pathophysiolog
cap
improv
infect
still
remain
signific
caus
morbid
mortal
need
better
diagnost
tool
allow
rapid
identif
etiolog
pathogen
potenti
marker
resist
must
redoubl
effort
use
antimicrobi
expediti
judici
possibl
research
adjunct
measur
manag
cap
necessari
well
la
mandel
receiv
consult
fee
bayer
cempra
nabriva
therapeut
lectur
fee
daiichi
sankyo
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
